#21 cfr 312 investigator responsibilities

[ccrpsorg]

Navigating 21 CFR 312: A Comprehensive Guide

Keeping Up with FDA Regulations and Requirements

What is 21 CFR 312?

21 CFR 312 is a set of regulations and requirements set out by the Food and Drug Administration (FDA). It details the procedures and processes that clinical trials must follow in order to be approved by the FDA. These regulations must be followed in order to ensure that the clinical trial being conducted is safe and beneficial for the participants.

21 CFR 312 is a federal regulation from the Code of Federal Regulations that outlines the requirements for Investigational New Drugs (INDs). This section of the code provides guidance to drug manufacturers and sponsors on what is required to have an IND approved by the Food and Drug Administration (FDA). It also addresses topics such as requirements for preclinical safety testing, clinical trials protocol design, and data collection.

The regulation begins by defining the meaning of investigational new drugs and explains how these drugs differ from other types of pharmaceutical products. It then outlines the requirements for initiation and oversight of clinical trials, including protocols for filing a Form 1571 with FDA prior to commencing any trial. 21 CFR 312 also requires sponsors to submit detailed information about their proposed clinical trials, including a description of study objectives, expected endpoints, investigator qualifications and selection criteria, as well as a description of any potential risks associated with participation in the study. Additionally, sponsors must provide evidence that the proposed protocol has been reviewed and approved by an Institutional Review Board (IRB) prior to submitting it to FDA.

21 CFR 312 further addresses essential documentation that must be included in any submission to FDA requesting approval for an IND. This includes an investigator's brochure containing information regarding safety data collected during previous studies conducted using similar compounds or agents; reports summarizing preclinical studies performed such as toxicity testing; as well as all reports prepared by investigators involved in conducting the clinical trial. The regulation also sets forth requirements regarding monitoring ongoing clinical trials and reporting any adverse events or serious unexpected events that occur during the course of a trial.

21 CFR 312 plays a critical role in providing drug manufacturers and sponsors with necessary guidance on how to develop safe drugs while adhering to important ethical considerations related to human research protection standards. As such, it serves an essential function in ensuring that new drugs are developed safely before they can be released into the market for public use.

Who Does 21 CFR 312 Affect?

21 CFR 312 affects a wide range of individuals, including physicians, researchers, sponsors, and institutional review boards (IRBs). All of these individuals must comply with 21 CFR 312 in order to ensure that the clinical trials they are conducting are conducted in a safe and ethical manner.

How Can I Stay Up to Date With 21 CFR 312?

Staying up to date with 21 CFR 312 is essential for those conducting clinical trials. The best way to stay up to date is to regularly review the 21 CFR 312 regulations and requirements, as well as any changes or updates that have been made. Additionally, you should regularly consult with an expert on 21 CFR 312 to ensure that you are following the regulations correctly and to answer any questions or concerns you may have.

21 CFR 312 is a subchapter of the Code of Federal Regulations (CFR) that establishes the requirements for human drug clinical trials in the United States. It covers the regulations for drug safety and efficacy studies, which can include both non-clinical and clinical trials. The regulations are designed to protect human subjects while ensuring the accuracy, integrity, and reliability of data used to support applications seeking approval from the Food and Drug Administration (FDA). The scope of 21 CFR 312 encompasses all phases of drug development, including pre-clinical research, clinical trials, post-marketing studies, adverse event reporting, and manufacturing.

Under this regulation, sponsors must submit an Investigational New Drug (IND) application to FDA before beginning any human drug trial in order to obtain permission to use an unapproved investigational drug or biologic product in a clinical trial. Sponsors must provide detailed information on the manufacturing process, composition, pharmacology/toxicology data from animal models, chemistry data from nonclinical laboratory tests, previous clinical experience with similar drugs or biologics products as well as an assessment of potential risks associated with use of the investigational product.

21 CFR 312 also requires sponsors to develop comprehensive protocols for each study or trial conducted under its jurisdiction. These protocols must specify objectives for each study and define what measurements need to be taken during each stage in order to ensure that appropriate safety measures are taken throughout the entire process. Additionally, protocols should be clearly written so that consistent results are obtained across multiple sites conducting trials with similar investigational products.

Finally 21 CFR 312 ensures that adequate provisions exist for informed consent forms given to participants in clinical trials so they understand their rights as subjects and any potential risks associated with participating in a particular study or trial.

Study Guide for 21 CFR 312

1. Overview: 21 CFR 312 is a part of Title 21 of the Code of Federal Regulations (CFR). It details the regulations, procedures, and requirements that must be met in order to conduct clinical investigations involving drugs and medical devices. These regulations are designed to ensure patient safety and protection during such testing.

2. Investigational New Drug Application (IND): Subpart A outlines an application process for any new drug intended for use in a clinical investigation. The IND must include information about the preclinical pharmacology, toxicology, and other activities related to the development of the drug as well as proposed protocols for clinical testing.

3. Investigator Responsibilities: Subpart B outlines the responsibilities of investigators conducting clinical trials with investigational drugs or devices. This includes obtaining informed consent from subjects, submitting reports on progress and adverse effects experienced by subjects, maintaining accurate records, and reporting any unanticipated problems or serious adverse events that occur during a trial.

4. Sponsor Responsibilities: Subpart C outlines the responsibilities of sponsors who are responsible for conducting or sponsoring clinical trials with investigational drugs or devices. This includes monitoring study sites to ensure compliance with good clinical practice standards and providing investigators with necessary safety information regarding any investigational products they may be using in their trials.

5. Institutional Review Boards (IRBs): Subpart D outlines guidelines for IRBs which are responsible for ensuring that all research involving human subjects is conducted ethically and according to FDA regulations. This includes reviewing protocols for clinical trials before they can begin and providing ongoing oversight throughout the course of a study so that patient rights are protected throughout the duration of a trial.

6. Termination or Suspension: Subpart E outlines provisions allowing FDA to terminate or suspend ongoing investigations if any safety concerns arise during a trial that could threaten subject safety or render data generated from a trial unreliable or invalid due to protocol violations or unethical practices by investigators or sponsors involved in an experiment

What is 21 CFR 312?

21 CFR 312 is a set of regulations issued by the US Food and Drug Administration (FDA) to establish good clinical practice (GCP) standards for conducting clinical trials. It covers the design, conduct, performance, monitoring, auditing, recording, analysis and reporting of clinical investigations conducted under FDA regulations.

What types of studies does 21 CFR 312 cover?

21 CFR 312 covers interventional studies that involve human participants or data from human participants used to determine the safety or effectiveness of a drug product. These studies may include phase I through IV clinical trials for new drug products as well as bioavailability/bioequivalence studies and post-marketing surveillance activities.

Who must comply with 21 CFR 312?

All sponsors and investigators who are involved in conducting clinical investigations subject to FDA jurisdiction must comply with 21 CFR 312. This includes all sponsors and investigators who submit an Investigational New Drug application (IND) to the FDA or an Abbreviated New Drug Application (ANDA).

What are the key requirements of 21 CFR 312?

The key requirements outlined in 21 CFR 312 include obtaining informed consent from study participants; providing accurate records; establishing quality assurance procedures; protecting the rights and welfare of study subjects; ensuring appropriate data collection and analyses techniques; evaluating data integrity; maintaining confidentiality of subjects and their information; training personnel involved in the trial on GCP protocols; preparing detailed reports of findings; establishing audit trails; gaining approval from an Institutional Review Board before beginning any trial activity and many more important elements.

How does 21 CFR 312 affect research ethics?

By complying with 21 CFR 312, researchers ensure that human subjects are treated ethically during clinical trials. Key ethical considerations that must be met include obtaining informed consent from study participants; protecting patient privacy; minimizing risk to patients participating in trials and ensuring proper oversight throughout the duration of the trial.

What is a sponsor's responsibility when conducting a clinical investigation covered under 21 CFR 312?

A sponsor’s responsibility under 21 CFR 312 includes developing adequate protocols for each investigation, selecting qualified investigators to ensure effective oversight, obtaining informed consent forms from all patients involved in any investigational activities, providing adequate safeguards regarding patient confidentiality, informing participants about potential risks associated with any investigational activities they may be engaged in and ensuring compliance with all applicable laws related to GCP related activities.

What role does an Institutional Review Board play when conducting a clinical investigation covered under 21CFR312?

An Institutional Review Board (IRB) has a critical role when conducting investigations subject to FDA jurisdiction as outlined in21CFR312. An IRB is responsible for reviewing protocols submitted by sponsors prior to commencing any investigational activity involving human subjects. The IRB also provides ongoing review and monitoring throughout the course of an investigation to ensure continued adherence to all applicable FDA regulations related to GCP standards outlined in 21CFR312.

What type of documentation must be maintained according to 21CFR312?

According to 21CFR312 sponsors must maintain documentation outlining the duties performed by each individual involved in any investigational activity related tot he trial including protocol development activities, informed consent process details etc.. In addition sponsors must keep thorough records detailing all data collected during each stage off the trial as well as facilitate audit trails so that investigators can easily trace back any changes made during analysis or reporting stages off thee trial process..

How often should audits take place according for 21CFR312 ?

Sponsors must perform audits at least annually according twenty one C F R three twelve The objective off these audits is two ensure compliance within applicable regulatory standards In some cases additional audits may be necessary depending on complexity off thee protocol being investigated or if unusual deviations occur during thee course off thee trial ..

When should sponsors provide reports to FDA based on their findings ?

Sponsors should provide reports too FDA based on their findings no later than thirty days after completion off thee investigation . If necessary , requesting additional time due two extenuating circumstances can bee performed before submitting report results .

Review Questions for 21 CFR 312

MCQ 1: What is the purpose of 21 CFR 312?

A. To establish rules and regulations for the production and sale of drugs

B. To protect public health by ensuring drug safety

C. To reduce the cost of pharmaceuticals

D. To create standards for food safety

Answer: B. To protect public health by ensuring drug safety. 21 CFR 312 is a section of federal regulations that are designed to ensure drug safety through the establishment of rules and regulations for their production, distribution, labeling, quality control and advertising. The primary goal of this regulation is to protect public health by guaranteeing that all pharmaceutical products meet minimum standards for efficacy, potency, purity and quality.

MCQ 2: What type of information must be included on a label in accordance with 21 CFR 312?

A.Ingredient list

B.Expiration date

C.Instructions for use

D.Nutritional value

Answer: A. Ingredient list. According to 21 CFR 312, all pharmaceutical labels must include an ingredient list containing information about all active ingredients used in the product as well as any inactive ingredients that make up more than 2% of the total weight or volume of the product. Additionally, labels must also include information about any colorants used as well as impurities present in trace amounts that could adversely affect users if consumed in large quantities over time.

MCQ 3: How often must pharmaceutical companies submit manufacturing records to the FDA?

A. Monthly

B. Annually

C. Quarterly

D. Biannually

Answer: C Quarterly. Pharmaceutical companies must submit detailed manufacturing records to the Food and Drug Administration (FDA) on a quarterly basis when filing reports required by 21 CFR 312, Subpart G-Requirements for Registration of Manufacturers/Processors/Packers/Holders (§312). This includes comprehensive records regarding quality control systems testing procedures, manufacturing facilities, operations specifications, equipment maintenance schedules and more that demonstrate compliance with FDA regulations for safe production practices and product quality assurance purposes

MCQ 4: What role does advertising play within 21 CFR 312?

A .It is permitted but heavily restricted

B .It is not mentioned at all

C .It is prohibited altogether

D .It is unrestricted

Answer : A It is permitted but heavily restricted. The advertising and promotion requirements outlined in 21 CFR 312 provide comprehensive guidance on how firms should market their products while remaining compliant with regulatory requirements set forth by the Food & Drug Administration (FDA). While these regulations do permit firms to advertise their products under certain conditions it also places several restrictions such as prohibiting false or misleading claims or engaging in deceptive practices when promoting their products

MCQ 5 : Which type of information can be shared between manufacturers when trading biological materials according to §312.50(a)(1)?

A .Confidential trade secrets

B .Patent information

C .Test results

D .Facility locations

Answer : C Test results. Section 312.50(a)(1) outlines which types of information can be shared between manufacturers when trading biological materials such as microorganisms or raw materials intended for use in animal feed or fertilizer applications, medicinal drugs or food additives etc.. Test results from safety analysis performed on such materials may be shared between manufacturers provided they have been adequately validated for accuracy prior to disclosure

MCQ 6: Which factors are taken into account when determining whether a clinical trial should be conducted?

A. The predicted risk or benefit associated with a drug's use

B. The number of participants needed in a study to obtain valid results

C. The cost associated with conducting the trial

D. All of the above

Answer: D. All of the above. 21 CFR 312 states that clinical trials must be conducted in order to determine whether a drug is safe and effective and that considerations such as potential risks, benefits, number of participants needed for valid results, and cost must all be taken into account when making this determination.

MCQ 7: When must an investigational new drug application (IND) be submitted according to 21 CFR 312?

A. When initiating any clinical investigations involving a new drug

B. When submitting new marketing applications for a drug product

C .When introducing any changes to an approved drug product

D .All of the above

Answer: A .When initiating any clinical investigations involving a new drug . According to 21 CFR 312, an IND must be submitted prior to initiating any studies or trials involving an investigational new drug or biologic agent in humans in order to ensure patient safety and health protection standards are met prior to initiation of these activities.

MCQ 8: What type of data is required when submitting an investigational new drug application (IND)? A . Clinical data from past trials involving similar products

B .Data on animal testing conducted using the proposed product

C .Data on manufacturing processes used during development

D .All of the above

Answer: D .All of the above . In order for an IND to be approved by FDA regulatory authorities all available information regarding preclinical studies, pharmacology/toxicology studies, chemistry manufacturing controls, previous clinical experience with similar products, proposed protocol(s), investigator qualifications must all be submitted alongside supporting documents outlining these details so that decisions can be made based on available data points provided in these documents.

MCQ 9: What type of review process takes place after submission of an investigational new drug application (IND)?

A . Statistical analysis using collected clinical data

B .A comprehensive evaluation by FDA regulatory experts

C .Approval from Institutional Review Board (IRB)

D .All of the above

Answer: D .All After submission of an IND both statistical analysis using collected clinical data as well as comprehensive evaluations by FDA regulatory experts take place in order for decisions about approval or rejection to be made; additionally Institutional Review Boards review all materials before approving studies or trials for conduct with human participants per FDA guidelines outlined in 21 CFR 312

CCRPS offers certification with 21 CFR 312 review in depth. Demo our courses today to learn more.

#21 cfr 312 #21 cfr part 312 #cfr 21 part 312 #21 cfr 312.32 #21 cfr 312.23 #21 cfr 312.62 #21 cfr 312.40 #21 cfr 312.60 #21 cfr 312.120 #21 cfr 312 investigator responsibilities #21 cfr 312 pdf #21 cfr 312 subpart d #21 cfr 312.110 #21 cfr 312.160 #21 cfr 312.2 #21 cfr 312.2 b #21 cfr 312.2 b 1 #21 cfr 312.20 #21 cfr 312.21 #21 cfr 312.21 a #21 cfr 312.21 b #21 cfr 312.22 #21 cfr 312.23 a 10 #21 cfr 312.23 a 2 #21 cfr 312.23 a 3 #21 cfr 312.23 a 5 #21 cfr 312.23 a 6 #21 cfr 312.23 a 6 iii b #21 cfr 312.23 a 7 #21 cfr 312.23 a 7 iv e

[californiaprelawland]

Protecting Children In A Digital Age

By Frances Conci, University of San Francisco Class of 2021

July 25, 2020

Last March, Governor Gavin Newsom gave his extensive-ranging State of the State address, he put forward an idea built upon last year’s passage of a sweeping new consumer privacy act. At the same 1time, not an entirely new concept, the particulars were yet to be decided. The idea that the companies who are profiting most from consumers’ personal information should be forced to share the bounty holds an undeniable appeal, ie. Data Dividend for Californias, a proposal by Governor Newsom.  The California Consumer Privacy Act of 2018 (CCPA) is a comprehensive new law that gives California consumers more control over the personal information that businesses may collect about California consumers.

This new landmark law secures robust privacy rights for California consumers, including:

1.The right to know about personal information a business collects about them and how it is used and shared. You may ask businesses to disclose what personal information they have about you and what they do with that information, to delete your personal information and not to sell your personal information.2

2.The right to delete personal information collected from them (with some exceptions). Personal information is information that identifies, relates to, or could reasonably be linked with to you or your household. It could include your name, social security number, email address, records of products purchased, internet browsing history, geolocation data, fingerprints, and inferences from other personal information that could create a profile about your preferences and characteristics.3

3. The right to opt-out of the sale of their personal information. You may request that businesses stop selling your personal information (“opt-out”).4

4.The right to non-discrimination for excessing CPPA rights. You can refuse to provide your personal information to a business or ask to delete or stop selling your personal information, and that personal information or sale is necessary for the business to provide you with goods or services, the business may not be able to complete that transaction.

On July 2, California began enforcing its new data privacy law- some are still looking for an understanding of what it means for consumers and businesses. This new law has been a thorn in the marketing industry's side, and companies rely heavily on data-driven advertising  The California Dept. of Justice secured 23 new positions to prepare for legal challenges and the new law enforcement.6Additionally, Attorney General Xavier Becerra has also urged consumers to alert the California Dept. of Justice if they think they’ve come across any potential CCPA violations.7 

While the CCPA gives adults the ability to protect their privacy, there must be a balance against the proliferation of digital-first crimes, including child sexual abuse, human trafficking, sexual exploitation, and other crimes against children. The world continues to connect virtually, leaving the inability to accurately protect those who can be victimized. Children’s Online Privacy Protection Act (COPPA), imposes specific requirements of websites or online services directed to children under 13 years of age, and on operators of other online services with actual knowledge that they are collecting personal information from a child under 13 years of age. Online communication can connect people all over the 8world but can also be maliciously used. Users who abuse online spaces can reach a broader audience of potential victims, conspire with others, and inflate their illegal activity while being protected by online anonymity. 

The challenge faced is to respect the rights to privacy of individuals while still allowing system controls to protect, detect, and investigate those who are purposely using the Internet to harm vulnerable users, altering their safety. Right now, just as there are laws forced in offline lives, legislation is to be tasked to 9protect online lives. Privacy rights and the risk of being victimized are in conflict. Merely complying with the COPPA requirements will not be sufficient to ensure CCPA compliance. The CCPA regulations require businesses to take reasonable steps to ensure that the person authorizing consent for the sale of a child’s data on their behalf is actually their parent or legal guardian. This regulation highlights that children can 10forge parental signatures or any other means of giving consent and does not allow businesses to turn a blind eye to the reasonableness of their consent mechanisms if they have actual knowledge that children under 13 use their website.11

Currently, one person's gain equivalent to another's loss is a mass perception for privacy and safety on digital platforms. The regulations and enforcements are confusing and difficult to navigate for companies. In 2009, the Child Online Protection Act (COPA) was overturned but, the Supreme Court on the foundation that it violated the first amendment rights. The practical implications of this legislative 12change, coupled with Section 230 of the Communications Decency Act (CDA) of 1996, holds that platforms are not responsible for what third-party publishers post on them. Leading to, that children are no longer protected from adult content by websites – the responsibility was transferred to their parents.13

The Children’s Online Privacy Protection Act of 1998 (COPPA) is the current law that protects child data privacy online. It mandates that any company with users of 13 and under on their platforms, must prove that their parents gave their permission and can not conserve data from children under 13. A handful of 14platforms avoid addressing said restrictions by stating that no one under the age of 13 is allowed on their sites, but lack practices in place for any form of proof of identity to enforce them purposefully.  They usually use a “check the box if you are over 13“ honor system, so many children online lack the privacy or safety protections that COPPA meant to provide them.15

Raising a child in the new age of a digital world is confusing, puzzling, and hard to maintain, as many parents are a novice in how social media platforms work. Children’s exposure to adult content has never been more easily accessible, and parents lack the knowledge to navigate and protect. This gap of knowledge leaves more room for children to experience cyberbullying, grooming, and sexual exploitation. Mental health issues are soaring amongst adolescent and teen Internet and social media users.16

The National Law Review states recommendations for businesses and child safety on their platforms. Companies that knowingly collect children’s PI should establish and implement one of the processes suggested in § 999.330(b) to reasonably ensure that the person providing consent for the sale of data is the child’s parent or guardian. Businesses should consider operational issues when determining which 17method or methods will be the least burdensome for them to implement, as well as carefully document such processes, and include descriptions in their privacy policy.1

________________________________________________________________

Jill Cowan, “How Much Is Your Data Worth?,” The New York Times (The New York Times, March 25, 12019), https://www.nytimes.com/2019/03/25/us/newsom-hertzberg-data-dividend.html.

California Consumer Privacy Act (CCPA). (2020, July 09).2See 23See 24See 25Marty Swant, “As Enforcement Of California's Privacy Law Begins, Industries Wonder What Comes Next,” July 4, 2020, https://www.forbes.com/sites/martyswant/2020/07/02/as-enforcement-of-californias-privacy-law-begins-industries-wonder-what-comes-next/.See 67 “Children's Online Privacy Protection Rule (‘COPPA’),”

Federal Trade Commission, March 6, 2020, 8https://www.ftc.gov/enforcement/rules/rulemaking-regulatory-reform-proceedings/childrens-online-privacy-protection-rule.“Analysis of Attorney General Regulations to CCPA – Part 4: Special Rules Regarding Minors,”

The 9National Law Review, accessed July 23, 2020, https://www.natlawreview.com/article/analysis-attorney-general-regulations-to-ccpa-part-4-special-rules-regarding-minors.See 910 See 911 H.R.3783 -

Child Online Protection Act- 105th Congress (1997-1998)12 Lisa Thee and July 21, “Digital Privacy: A Double-Edged Sword,” Help Net Security, July 20, 2020, 13https://www.helpnetsecurity.com/2020/07/21/global-digital-privacy/.

Federal Trade Commission 16 CFR Part 312 Children’s Online Privacy Protection Rule14 See 1315 See 1316 See 917 See

Photo Credit: caprivacy.org